Skip to main content
Erschienen in: Endocrine Pathology 4/2018

25.09.2018

TEKT4 Promotes Papillary Thyroid Cancer Cell Proliferation, Colony Formation, and Metastasis through Activating PI3K/Akt Pathway

verfasst von: Zhouci Zheng, Xiaofen Zhou, Yefeng Cai, Endong Chen, Xiaohua Zhang, Ouchen Wang, Qingxuan Wang, Haiguang Liu

Erschienen in: Endocrine Pathology | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Thyroid carcinoma is the most common malignancy of the endocrine system worldwide, but its molecular mechanisms remain unclear. Some diseases are associated with TEKT4 gene. However, its role in thyroid carcinoma has yet to be fully examined. This study was designed to investigate the function of TEKT4 in papillary thyroid cancer (PTC). The effect of TEKT4 on aggressive behavior of PTC cell lines, namely, TPC1 and BCPAP, transfected with small interfering RNA was identified through cell proliferation, colony formation, migration, and invasion. Our previous study revealed that TEKT4 may be vital in PTC. In in vitro experiments, TEKT4 downregulation suppressed cell proliferation, colony formation, cell migration, and invasion. Our data also indicated that tumor-suppressing role of TEKT4 knockdown in PTC cell lines was associated with the silence of the PI3K/Akt pathway. Our study revealed that TEKT4 shows important biological implications and is worthy of further study.
Literatur
1.
Zurück zum Zitat Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: a cancer journal for clinicians. 2015;65(1):5–29. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: a cancer journal for clinicians. 2015;65(1):5–29.
2.
Zurück zum Zitat Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J Cancer statistics in China, 2015. CA: a cancer journal for clinicians. 2016;66(2):115–132. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J Cancer statistics in China, 2015. CA: a cancer journal for clinicians. 2016;66(2):115–132.
3.
Zurück zum Zitat Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer research. 2014;74(11):2913–2921.CrossRef Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer research. 2014;74(11):2913–2921.CrossRef
4.
Zurück zum Zitat Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nature reviews Cancer. 2013;13(3):184–199.CrossRef Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nature reviews Cancer. 2013;13(3):184–199.CrossRef
5.
Zurück zum Zitat Xing M. BRAF mutation in thyroid cancer. Endocrine-related cancer. 2005;12(2):245–262.CrossRef Xing M. BRAF mutation in thyroid cancer. Endocrine-related cancer. 2005;12(2):245–262.CrossRef
6.
Zurück zum Zitat Xing M. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid : official journal of the American Thyroid Association. 2010;20(7):697–706.CrossRef Xing M. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid : official journal of the American Thyroid Association. 2010;20(7):697–706.CrossRef
7.
Zurück zum Zitat Gustafson S, Zbuk KM, Scacheri C, Eng C. Cowden syndrome. Seminars in oncology. 2007;34(5):428–434.CrossRef Gustafson S, Zbuk KM, Scacheri C, Eng C. Cowden syndrome. Seminars in oncology. 2007;34(5):428–434.CrossRef
8.
Zurück zum Zitat Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K, Vasko V, el-Naggar AK, Xing M Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. The Journal of clinical endocrinology and metabolism. 2008;93(8):3106–3116.CrossRef Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K, Vasko V, el-Naggar AK, Xing M Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. The Journal of clinical endocrinology and metabolism. 2008;93(8):3106–3116.CrossRef
9.
Zurück zum Zitat Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan AK, Sun H, el-Naggar AK, Xing M Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocrine-related cancer. 2013;20(4):603–610.CrossRef Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan AK, Sun H, el-Naggar AK, Xing M Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocrine-related cancer. 2013;20(4):603–610.CrossRef
10.
Zurück zum Zitat Amos LA. The tektin family of microtubule-stabilizing proteins. Genome biology. 2008;9(7):229.CrossRef Amos LA. The tektin family of microtubule-stabilizing proteins. Genome biology. 2008;9(7):229.CrossRef
11.
Zurück zum Zitat Roy A, Lin YN, Agno JE, DeMayo FJ, Matzuk MM. Absence of tektin 4 causes asthenozoospermia and subfertility in male mice. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2007;21(4):1013–1025.CrossRef Roy A, Lin YN, Agno JE, DeMayo FJ, Matzuk MM. Absence of tektin 4 causes asthenozoospermia and subfertility in male mice. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2007;21(4):1013–1025.CrossRef
12.
Zurück zum Zitat Wu WB, Li YS, Ji XF, Wang QX, Gao XM, Yang XF, et al. [Expression of TEKT4 protein decreases in the ejaculated spermatozoa of idiopathic asthenozoospermic men]. Zhonghua nan ke xue = National journal of andrology. 2012;18(6):514–517.PubMed Wu WB, Li YS, Ji XF, Wang QX, Gao XM, Yang XF, et al. [Expression of TEKT4 protein decreases in the ejaculated spermatozoa of idiopathic asthenozoospermic men]. Zhonghua nan ke xue = National journal of andrology. 2012;18(6):514–517.PubMed
13.
Zurück zum Zitat Jiang YZ, Yu KD, Peng WT, Di GH, Wu J, Liu GY, et al. Enriched variations in TEKT4 and breast cancer resistance to paclitaxel. Nature communications. 2014;5:3802.CrossRef Jiang YZ, Yu KD, Peng WT, Di GH, Wu J, Liu GY, et al. Enriched variations in TEKT4 and breast cancer resistance to paclitaxel. Nature communications. 2014;5:3802.CrossRef
14.
Zurück zum Zitat Wang QX, Chen ED, Cai YF, Zhou YL, Zheng ZC, Wang YH, Jin YX, Jin WX, Zhang XH, Wang OC Next-generation sequence detects ARAP3 as a novel oncogene in papillary thyroid carcinoma. OncoTargets and therapy. 2016;9:7161–7167.CrossRef Wang QX, Chen ED, Cai YF, Zhou YL, Zheng ZC, Wang YH, Jin YX, Jin WX, Zhang XH, Wang OC Next-generation sequence detects ARAP3 as a novel oncogene in papillary thyroid carcinoma. OncoTargets and therapy. 2016;9:7161–7167.CrossRef
15.
Zurück zum Zitat Cancer Genome Atlas Research N. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159(3):676–690.CrossRef Cancer Genome Atlas Research N. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159(3):676–690.CrossRef
16.
Zurück zum Zitat Robenshtok E, Nachalon Y, Benbassat C, Hirsch D, Shimon I, Grossman A, Diker-Cohen T, Akirov A, Popovtzer A Disease Severity at Presentation in Patients with Disease-Related Mortality from Differentiated Thyroid Cancer: Implications for the 2015 ATA Guidelines. Thyroid : official journal of the American Thyroid Association. 2017;27(9):1171–1176.CrossRef Robenshtok E, Nachalon Y, Benbassat C, Hirsch D, Shimon I, Grossman A, Diker-Cohen T, Akirov A, Popovtzer A Disease Severity at Presentation in Patients with Disease-Related Mortality from Differentiated Thyroid Cancer: Implications for the 2015 ATA Guidelines. Thyroid : official journal of the American Thyroid Association. 2017;27(9):1171–1176.CrossRef
Metadaten
Titel
TEKT4 Promotes Papillary Thyroid Cancer Cell Proliferation, Colony Formation, and Metastasis through Activating PI3K/Akt Pathway
verfasst von
Zhouci Zheng
Xiaofen Zhou
Yefeng Cai
Endong Chen
Xiaohua Zhang
Ouchen Wang
Qingxuan Wang
Haiguang Liu
Publikationsdatum
25.09.2018
Verlag
Springer US
Erschienen in
Endocrine Pathology / Ausgabe 4/2018
Print ISSN: 1046-3976
Elektronische ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-018-9549-0

Weitere Artikel der Ausgabe 4/2018

Endocrine Pathology 4/2018 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …